#China #Guangzhou #AI Solutions #Fangzhou Inc. #Hepatitis Control

Fangzhou Partners for Hepatitis Training Center

Fangzhou Inc., a frontrunner in artificial intelligence-driven healthcare innovations, has recently embarked on a significant collaboration with the Guangdong Provincial Liver Disease Institute. This partnership was formally introduced during the 2025 Greater Bay Area International Liver Disease Forum, held in Guangzhou, China. The initiative has given birth to the "AI + Hepatitis Prevention and Control Training Center", signifying a giant leap towards advancing liver disease management using sophisticated AI technologies.

The Vision Behind the Partnership

Dr. Xie Fangmin, who serves as the founder, chairman, and CEO of Fangzhou, expressed the essence of this partnership by stating, "Our role in establishing this training center highlights the Company's technological excellence and commitment to social responsibility." This initiative intends to bridge the gap between AI advancements and traditional liver disease treatment methods. By integrating cutting-edge technology with the Institute's clinical experience, the goal is to enhance accessibility to high-quality hepatology care.

Fangzhou aims to implement smart screening tools along with AI-assisted treatment protocols, which are expected to redefine benchmarks in liver disease prevention and care management. As the World Health Organization sets the ambitious goal of eliminating viral hepatitis as a major public health issue by 2030, Fangzhou is steadfast in its commitment to improving patient well-being through innovative solutions.

Targeting the Future of Liver Disease Management

The establishment of the Training Center not only highlights Fangzhou’s achievements in AI-enabled full-cycle liver disease management but also sets a forward-looking agenda for the future. The company is keen on continuing its journey of leveraging advanced artificial intelligence technologies to better combat liver diseases. Their focus will remain on enhancing standards for comprehensive care, ensuring that patients receive the utmost support from prevention through treatment.

The center will serve not only as an educational platform, helping medical professionals stay abreast of the latest innovations, but also push the agenda of synergistic collaboration between research and clinical practice. This approach is expected to expedite Guangdong’s efforts in addressing the public health concerns posed by viral hepatitis.

About Fangzhou Inc.

Fangzhou Inc. is recognized as China’s pioneering online chronic disease management platform. As of the end of December 2024, the company had a substantial user base, comprising over 49.2 million registered users and 223,000 physicians. The company specializes in personalized medical care and precision medicine solutions, setting high standards in the healthcare industry. More information about Fangzhou’s offerings can be accessed via Fangzhou’s Investor Relations website.

The Greater Bay Area International Liver Disease Forum

The 2025 forum brought together esteemed representatives from various sectors, including government, industry, academia, and medicine, all focused on addressing the cutting-edge developments in hepatology. The forum facilitated expert presentations and profound discussions which contributed to establishing a robust academic exchange framework aimed at eliminating viral hepatitis and improving liver disease diagnosis and management. This collaborative event has fostered an environment where clinical practice and scientific research can thrive together.

In conclusion, Fangzhou Inc.'s partnership with the Guangdong Provincial Liver Disease Institute signals a significant and promising step towards integrating AI in liver disease management, ultimately benefiting patients and healthcare providers alike, and marking a vital move in the global fight against hepatitis.